MedTrace Logo

Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm

NCT01632267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2016-01-05

Study results available
· View outcomes & findings →

Summary

Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial. The financial burden of treatment failures in direct treatment costs, disability, decreased productivity, and missed work may in part derive from a mismatch between optimal, and actual, medications prescribed. The present one year retrospective study seeks to evaluate the indirect and direct healthcare costs for 96 patients with a DSM-IV-TR depressive or anxiety disorder, in relation to an interpretive reporting system designed to predict antidepressant responses based on DNA variations in cytochrome P450 genes (CYP2D6, CYP2C19, CYP1A2), the serotonin transporter gene (SLC6A4), and the serotonin 2A receptor (5HTR2A) genes.

Conditions

Sponsors & Collaborators

  • Assurex Health Inc.

    lead INDUSTRY

Principal Investigators

  • Aida Spahic-Mihajlovic, MD · Union Health Services

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-04-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01632267 on ClinicalTrials.gov